Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Summarizing adverse events reported to the FDA, 6 definite cases of intravascular hemolysis (hemoglobinuria/hemoglobinemia and/or DIC) are detailed after administration of anti-D IGIV (WinRho). Several patients developed intravascular hemolysis after previously uncomplicated anti-D IGIV. Five patients were adults and all died. This study not only demonstrates that potentially fatal acute intravascular hemolysis may occur after anti-D IGIV and the importance of post-marketing surveillance.

DIC and Hemolysis after WinRho Treatment for ITP